| Date | Title | Description | |
|---|---|---|---|
| 02 Mar 2021 | On business and financial situation | The Company releases a presentation related to an update of the regulatory processes of its long-acting injectable antipsychotic, Doria®, both in Europe and the United States | Download |
| 24 Feb 2021 | About corporate governance | The Company informs about the agreements adopted by the Board of Directors | Download |
| 27 Nov 2020 | On business and financial situation | The Company publishes the results of the PRISMA-3 study of the efficacy and safety of Doria® in schizophrenic patients in the journal npj Schizophrenia | Download |
| 09 Jul 2020 | On business and financial situation | ROVI informs on the Collaboration with Moderna for Outside the United States Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Feb 2020 | Annual Corporate Governance Report | ROVI releases the 2019 Annual Corporate Governance Report | Download |
| 26 Feb 2020 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2019 annual report regarding remuneration of the members of the Board of Directors | Download |
Pages
| Date | Title | Description | |
|---|---|---|---|
| 26 Jul 2018 | Información sobre resultados | ROVI releases the press release related to the 2018 first half financial results | Download |
| 02 Jul 2018 | Contratos de liquidez y contrapartida | Liquidity contract: transactions conducted in the second quarter of 2018 | Download |
| 22 Jun 2018 | Información sobre dividendos | The Company informs about the dividends payment | Download |
| 12 Jun 2018 | Otros sobre negocio y situación financiera | Corporate presentation update | Download |
| 29 May 2018 | Convocatorias y acuerdos de Juntas y Asambleas generales | ROVI releases the information related to its General Shareholders Meeting | Download |